www.kisupplements.
org
1
Department of Medicine,
Division of Nephrology, University
of British Columbia, Vancouver,
British Columbia, Canada;
2
Department of Nephrology and
Hypertension, University of
Erlangen-Nrnberg, Erlangen,
Germany; and 3Department of
Medicine, University of Calgary,
Calgary, Alberta, Canada
Correspondence: Adeera
Levin, University of British
Columbia, St. Pauls Hospital,
1081 Burrard Street, Room
6010A, Vancouver, British
Columbia V6Z1Y8, Canada.
E-mail: alevin@
providencehealth.bc.ca
4
GKHS Co-chairs.
Kidney International Supplements (2017) 7, 6162
The Global Kidney Health Summit
Outputs: details to guide the
nephrology community along the
road to global kidney health
Adeera Levin1,4, Kai-Uwe Eckardt2,4 and Marcello Tonelli3,4
Kidney International Supplements (2017) 7, 6162; http://dx.doi.org/10.1016/j.kisu.2017.07.001
Copyright 2017, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
he articles in this edition of Kidney In-
T ternational Supplements describe the
background, rationale, and action plans
on how to improve global kidney health.
Despite advances in the diagnosis and classi-
cation of kidney diseases and some technolog-
ical advances in the delivery of dialysis and
transplantation therapies, nephrology remains
behind many other medical specialties in terms
of effective therapies and lacks a solid evidence
base on which to establish therapeutic decisions
for our patients.
The International Society of Nephrology
convened a Global Kidney Health Summit in
Vancouver in July 2016. Eight-ve international
experts in epidemiology, translational sciences,
clinical trials, and clinical care, including in-
dustry partners and scientists, reviewed the
relevant background and developed a roadmap,
complete with a performance measurement
framework, which was published in The
Lancet.1 The roadmap describes the aspects of
care, research, and policy that must be
addressed to improve global kidney health. The
summit was supported by unrestricted educa-
tional grants from various industry partners
and the International Society of Nephrology. In
addition, the International Society of
Nephrology has developed the Global Kidney
Health Atlas to describe the state of kidney care
by documenting the status of the six dimensions
of universal health coverage. The overall results
of the Global Kidney Health Atlas can be found
at www.theisn.org and a peer-reviewed publi-
cation in The Journal of the American Medical
Association.2
This edition of Kidney International Supple-
ments presents a more in-depth description of
introduction
higher level goals and strategies described in
The Lancet roadmap,1 as well as the specic
protocol for the Global Kidney Health Atlas. A
detailed action plan for determining and
monitoring the prevalence of chronic kidney
disease (CKD) is described by Coresh and
colleagues3; a comprehensive list of risk factors
present around the world for both acute and
CKDs is presented with recommendations on
how to address the risk factors from the
perspective of sustainable development goals is
described by Luyckx et al.4; and Obrador,
Kttgen, and colleagues5 describe the impor-
tance of integration of knowledge from genetics
and gene-environment interactions. In the
article by Pea et al., the importance of sys-
tematic evaluation of disease progression, both
renal and extra-renal, and the quest for
meaningful prognostic biomarkers are
addressed.6 Jardine and colleagues7 examine
the paradox that even when we have evidence
to guide therapies in CKD populations, clinical
practice does not necessarily reect that data;
Bello et al.8 describe the specic complications
of CKD, including anemia and cardiovascular
disease, and how best to address the gaps in our
knowledge about the complex interaction
between cardiovascular disease and CKD.
Pollock, Zuk, and coauthors describe a robust
and interactive program by which establishing
and validating novel therapeutic targets to
retard the progression of CKDs will be effected;
partnerships between academics and the
industry are essential to ensure the success of
these endeavors.9 Lastly, Perkovic, Levey, and
colleagues10 describe challenges related to the
conduct of clinical research and clinical trials
and include suggestions for improvement.
61
introduction
Each article attempts to include perspectives
from around the globe, to represent the current
state of knowledge as well as critically evaluate
the gaps, and to offer concrete solutions to 2.
address those gaps. We look forward to the next
decade, in which we expect to see improve- 3.
ments in global kidney care due to the work of
these authors and the kidney clinical and aca-
demic communities. 4.
DISCLOSURE
5.
All the authors declared no competing interests.
Publication of this article was supported by the
International Society of Nephrology. 6.
ACKNOWLEDGMENTS
These manuscripts emerged as individual products of
the Global Kidney Health Summit held in Vancouver, 7.
Canada in July 2016. Support of the summit was
made possible through unrestricted grants from
various organizations in addition to the International 8.
Society of Nephrology. These include (in alphabetical
order) AbbVie Inc., Akebia Therapeutics Inc., Amgen,
AstraZeneca LP, Boehringer Ingelheim-Lilly, Danone 9.
Nutricia Research, Janssen Canada, Merck Global, and
Regulus Therapeutics Inc.
10.
REFERENCES
1. Levin A, Tonelli M, Bonventre J, et al. Global kidney
health 2017 and beyond: a roadmap for closing gaps
62
in care, research, and policy [e-pub ahead of print.]
The Lancet. Available at: http://www.sciencedirect.
com/science/article/pii/S0140673617307882.
Accessed August 9, 2017.
Bello AK, Levin A, Tonelli M, et al. Assessment of
Global Kidney Health Care Status. JAMA. 2017;317(18):
18641881.
Coresh J, Hu J-R, Bello A, et al. Action plan for
determining and monitoring the prevalence of
chronic kidney disease. Kidney Int Suppl. 2017;7:
6370.
Luyckx VA, Tuttle KR, Garcia-Garcia G, et al. Reducing
major risk factors for chronic kidney disease. Kidney Int
Suppl. 2017;7:7187.
Obrador GT, Schultheiss UT, Kretzler M, et al. Genetic
and environmental risk factors for chronic kidney
disease. Kidney Int Suppl. 2017;7:88106.
Pena MJ, Stenvinkel P, Kretzler M, et al. Strategies
to improve monitoring disease progression,
assessing cardiovascular risk, and dening
prognostic biomarkers in CKD. Kidney Int Suppl. 2017;7:
107113.
Jardine MJ, Kasiske B, Adu D, et al. Closing the gap
between evidence and practice in chronic kidney
disease. Kidney Int Suppl. 2017;7:114121.
Bello AK, Alrukhaimi M, Ashuntantang GE, et al.
Complications of CKD: current state, knowledge gaps,
and strategy for action. Kidney Int Suppl. 2017;7:
122129.
Pollock C, Zuk A, Anders H-J, et al. The establishment
and validation of novel therapeutic targets to retard
progression of chronic kidney disease. Kidney Int
Suppl. 2017;7:130137.
Perkovic V, Craig JC, Chailimpamontree W, et al. Action
plan for optimizing the design of clinical trials in
chronic kidney disease. Kidney Int Suppl. 2017;7:
138144.
Kidney International Supplements (2017) 7, 6162